◆ 会议时间：2024年7月22-25日
◆ 会议地点：美国 芝加哥

◆ 会议简介：

2024年美国心脏协会(AHA)基础心血管科学年会(BCVS2024)将于2024年7月22-25日在美国芝加哥举行，会议由美国心脏协会(AHA)主办。美国心脏协会BCVS年会力求通过心血管疾病的新疗法和见解，以及对微RNAs、心脏基因和细胞治疗、心脏发育以及组织工程和iPS细胞等领域宣的研究，来改善基本的心血管调节。BCVS年会将汇集来自世界各地的基础和转化心血管科学家，他们共同的目标是发现心血管治疗的途径，促进心血管健康。上届BCVS年会有超过1000余名专业人士参会，与会者包括：基础心血管科学家，分子/细胞生物学家，生理学家，转化研究者，临床试验者，执业心脏病专家，心血管护士和药剂师等等（未经许可禁止复制摘录转载本站任何内容-领域国际医学会议网）。

美国心脏协会（AHA）成立于1924年，是全球心血管领域学术影响力最大、历史最悠久的学术团体，致力于心脏病和卒中的预防与治疗，提供相关继续教育、流行病学年度报告。AHA拥有超过2250万名志愿者和支持者。

AHA Basic Cardiovascular Sciences (BCVS) Scientific Sessions 2024

Date: July 22-25, 2024
Venue: Hilton Chicago, Chicago, Illinois USA

摘要征文投稿：

January 10, 2024 : Abstract and Awards submissions OPEN

March 13, 2024 : Abstract and Awards submissions CLOSED

点此提交摘要>>>Submit Abstract>>>

To ensure that your abstract receives proper scientific consideration, be sure to submit to the appropriate category.

Abstract Submission

• Review Best Practices for Writing Abstracts on this page.
  
• All abstracts must be submitted (and if accepted, will be presented) in English, having accurate grammar and spelling suitable for publication.
  
• Statistical results (including descriptive and inferential statistics) are to be included.
  
• Author must affirm the work submitted is original and all statements declared as facts are based on thorough examination and investigation for accurateness.
  
• Authors should not "split" data to create several abstracts from one. If splitting is judged to have occurred, prior scores of related abstracts will be negatively influenced.
  
• Abstracts containing identical or nearly identical data submitted from the same institution and/or individuals will be disqualified.
  
• Proofread abstracts carefully to avoid errors before submission. The abstract will be published exactly as submitted.
  
• Submission of an abstract constitutes a commitment by the author(s) to present if accepted. Failure to present, if not justified, will jeopardize future acceptance of abstracts for American Heart Association meetings/conferences.
  
• There is no limit to the number of abstracts an investigator may submit. If selected, the presenter must be one of the co-authors listed. If multiple submissions are accepted, the presenting author must resolve schedule conflicts by arranging for a co-author to present.
• The work covered by the abstract must not have been presented at a national or international meeting before presentation at BCVS 2024, unless the submission includes incremental information from the abstract presented elsewhere to justify submission and presentation at the AHA. Each investigator will determine, in good conscience, what constitutes incremental information.
• Abstracts associated with a published manuscript can be presented at an AHA scientific event if the manuscript was published after the time the abstract was submitted to the event, however the abstract will not be published as a part of the journal publication.

Abstract Title

• An abstract must have a short, specific title (containing no abbreviations or inflammatory language) that indicates the nature of the investigation.
  
• Avoid an abstract title that reveals the results of the study. Explicit titles denoting the findings should be used (not “Investigations of…”, “Studies of…,” etc.)

Abstract Text

• It is recommended abstracts have the following identifiable sections:
  • Introduction/Background
  • Research Questions/Hypothesis
  • Goals/Aims
  • Methods/Approach
  • Results/Data (descriptive and inferential statistics)
  • Conclusion(s)
    
• Looking for recommendations on how to improve your abstract? We highly recommend you view these recommendations from AHA journals.
  
• Use generic drug names.
  
• Avoid beginning sentences with numbers.
  
• Standard abbreviations may be used without definition. Nonstandard abbreviations (kept to a minimum) must be placed in parentheses after the first use of the word or phrase abbreviated.
  
• Do not include references, credits or grant support.
  
• Do not include the names or personal information of any patient participating in the study or trial.

Abstract Character Guidelines

• Abstracts are limited to 1,950 characters (about 300-350 words).
  
• Spaces do not count as characters.
  
• Counts towards character limit include:
  • Text in the abstract body
  • Graphics – addition of an image, whether a figure or a table, deducts 250 characters.
    
    
• Does not count towards character limit:
  • Title of abstract
  • Names of authors
  • Spaces in the abstract body
  • Caption of graphic
    
    
• Graphics Guidelines
  
  • All graphics (figures) and text-based graphics (tables) should be provided as 72-300—dpi, pre-sized, .BMP, .GIF, .JPG or .PNG images only, with a maximum width of 440 pixels (no limit on length). Black-and-white digital images should be in grayscale mode. Color images should be saved in RGB mode.
    
  • All graphics will require a brief description of the image.
    
  • Please Note: If an abstract is accepted for publication, any images submitted with the abstract are placed after the abstract that will appear in the online-only supplement to Circulation Research, an American Heart Association journal.

Author Name(s)

• The submitting author will be designated as the primary and presenting author unless otherwise specified. The presenting author must be listed on the abstract and can be listed anywhere in the author block.
  
  
• Please review the author block carefully. Edits cannot be made after the March 13, 6:00 PM CDT/UTC-5 deadline. Once submission is complete, the author block will be published as submitted. Additions or deletions of author names are not permitted after the submission deadline.

Abstract Revisions

• After the deadline, your abstract submission is considered final and cannot be edited.
  • Abstracts may not be revised in any way or resubmitted.
  • Additions or deletions of author names will not be permitted.
    
    
• Proofread abstracts carefully to avoid errors before submission.

Abstract Copyright Transfer Agreement

• Abstract Copyright Transfer Agreement will be electronically signed during submission.
  • Your selection of “Yes” will grant permission to publish.
  • Your selection of “No” will prohibit publication of the abstract in all formats including the Circulation Research supplement, ePoster site, and the online program planner.

Abstract Review

• Abstracts successfully submitted by the March 13, 2024, 6:00 pm CDT/UTC -5 deadline are posted to a secured web site for blind review. Our intent is to be inclusive of quality science received without compromising scientific integrity. As such, a team of experts, selected by the BCVS Program Committee, independently reviews abstracts in the category that best fits their expertise.
  
  
• Abstracts submitted for consideration must convey an original idea, concept, or an improvement or revision of a previous idea. Abstracts are selected on the basis of the following:
  • Scientific merit - direction toward the development of a new or improved diagnostic procedure or idea.
  • Organization - well organized, easy to follow and understand.
  • Practicality - should be available, logical and feasible.
  • Presentation - should be clear, brief, show understanding of the subject matter.
  • Technical quality - the idea must stand up to scrutiny. Facts and data have scientific backing.

Abstract Acceptance

• Abstract acceptance/non-acceptance status will be available by mid-May. Please ensure the email provided for the presenting author is accurate as all correspondence will be sent via email, to the presenting author only.
  
  
• All communications regarding your abstract will be sent from specialtyconferences.participant@heart.org. Please make sure to add this email address to your email contacts to ensure important program participant related information gets through your spam filters, etc.
  
• All accepted abstracts will be scheduled either in an oral or poster presentation format. All presentations including question-and-answers will be conducted in English. Presenters may request assistance from the moderator who will repeat or rephrase questions from the audience or may ask a colleague in the audience to assist with translation.
  
• Guidelines for abstract presentation will be included in the acceptance communication.

Abstract Journal Publication

• Accepted abstracts having selected “Yes” to the Abstract Copyright Transfer Agreement will be published online in the Circulation Research journal supplement.

Embargo Policy

• Non-late breaking abstracts and presentations are embargoed for release at date and time of presentation for oral abstract presentations; and July 22, 2024 at 8:00 am Central Time for all poster presentations, and are therefore prohibited from release until date and time of AHA designated embargo time. You will be contacted by AHA communications if you are selected to participate in an AHA news event. NOTE: If presenting an abstract at the Asian Cardiovascular Symposium held on Sunday, July 21, 2024, the embargo will be lifted on date/time of presentation for oral sessions and July 21, 2024, at 1:00p pm Central Time for poster presentations.


• Written embargoed information cannot be shared with anyone outside of the AHA with the exception of a journal manuscript where one-on-one embargoed media interviews can be conducted as long as the reporter agrees to abide by the embargo policy. Failure to honor embargo policies will result in this abstract being withdrawn and future abstracts also being barred from presentation. Complete AHA Embargo Policy.

Recording Policy

• Unauthorized recording of the AHA Scientific Sessions, scientific conferences, and the AHA/ASA International Stroke Conference is prohibited, whether by video, still or digital photography, audio or any other recording or reproduction mechanism. This includes recording of presentations and supporting audiovisual materials and of poster presentations and supporting poster materials.
  
• The American Heart Association and American Stroke Association reserve the rights to all recordings or reproductions of presentations at AHA/ASA scientific conferences and meetings.

Use of Automated Assistive Writing Technologies and Tools

• The use of automated assistive writing technologies and tools (commonly referred to as artificial intelligence or machine learning tools) is permitted provided that their use is documented, and authors assume responsibility for the content. As with human-generated content, authors are responsible for the accuracy, validity, and originality of computer-generated content. Automated assistive writing technologies do not qualify for authorship as they are unable to provide approval or consent for submission.
  
• If the use of these technologies has involved the research design, the tools should be documented in the Methods. For additional information, see the World Association of Medical Editor recommendations.
  
• For your abstract submission, you will need to indicate the use of these tools.

Important Message to Abstract Submitters

The AHA has moved to a single sign-on process for submitting abstracts and disclosures through our website, Professional Heart Daily.

• Abstract submitters must have a username and password on Professional Heart Daily to complete their abstract submission when submitting to any AHA scientific meeting.
  
  
• If you do not remember your Professional Heart Daily login information or need to update your personal profile, do not create a new account. Please reach out to AHA Customer Service for assistance:
  
  AHA Customer Service
  (888) 242-2453 (Inside U.S.)
  (214) 570-5935 (Outside U.S.)
  Email: professional.help@heart.org
  
  Hours of Operation:
  Monday-Friday, 8 a.m. – 5 p.m. CT
  
  
• The AHA is now required to collect financial disclosures from all abstract submitting authors and co-authors.
  • As the submitting author, please be prepared to provide all co-author emails.
  • Co-authors without a complete disclosure will receive separate correspondence to submit this information.

◆ 参会对象：基础心血管科学家，分子/细胞生物学家，生理学家，转化研究者，临床试验者，执业心脏病专家，心血管护士和药剂师等等。